vTv Therapeutics Inc.

NasdaqCM:VTVT Stock Report

Market Cap: US$47.7m

vTv Therapeutics Past Earnings Performance

Past criteria checks 0/6

vTv Therapeutics's earnings have been declining at an average annual rate of -10.4%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 30.2% per year.

Key information

-10.4%

Earnings growth rate

19.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-30.2%
Return on equity-126.8%
Net Margin-1,830.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

Aug 24
Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

May 11
Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

vTv Therapeutics GAAP EPS of -$0.04

Aug 16

vTv stock soars 18% on $10M equity investment by CinRx Pharma

Jul 25

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

Aug 17
We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

Mar 03
The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

vTv Therapeutics inks licensing deal for HPP971, shares up 11%

Dec 15

Revenue & Expenses Breakdown

How vTv Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:VTVT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-18140
30 Jun 241-2013-3
31 Mar 241-21120
31 Dec 230-20120
30 Sep 230-22120
30 Jun 230-19128
31 Mar 230-17100
31 Dec 222-19120
30 Sep 222-21150
30 Jun 225-18140
31 Mar 225-16150
31 Dec 214-13110
30 Sep 2110-590
30 Jun 217-580
31 Mar 217-870
31 Dec 206-870
30 Sep 200-1570
30 Jun 200-1780
31 Mar 202-1790
31 Dec 193-1890
30 Sep 197-1590
30 Jun 1911-1190
31 Mar 1911-1290
31 Dec 1812-990
30 Sep 188-11100
30 Jun 185-14100
31 Mar 182-15110
31 Dec 170-16110
30 Sep 170-16110
30 Jun 170-16100
31 Mar 170-17100
31 Dec 161-16100
30 Sep 161-15100
30 Jun 161-16100
31 Mar 161-22100
31 Dec 151-2790
30 Sep 151-3290
30 Jun 151-3480
31 Mar 152-3190
31 Dec 142-36120
31 Dec 131-4880

Quality Earnings: VTVT is currently unprofitable.

Growing Profit Margin: VTVT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VTVT is unprofitable, and losses have increased over the past 5 years at a rate of 10.4% per year.

Accelerating Growth: Unable to compare VTVT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VTVT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: VTVT has a negative Return on Equity (-126.77%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:28
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

vTv Therapeutics Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Corey DavisCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.